Y-mAbs Therapeutics A/S
Public limited companyCVR 37053678HørsholmActive
Y-mAbs Therapeutics A/S is a public limited company, based in Hørsholm, active in research and experimental development on natural sciences and engineering, founded in 2015. Equity was negative at the end of 2025 (−DKK 163.7m). The company made a loss in both 2024 and 2025, most recently DKK 38.5m. Gross profit is higher than that of 90% of the companies in the industry in the database.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 61% (2024 → 2025), to DKK 29.3m.
- The loss grew: from DKK 12.5m to DKK 38.5m (2024 → 2025).
Employees
- 21 fewer employees than a year earlier: 13 (07/2026) against 34 (07/2025).
Management and owners, last 24 months
- New in management: Antoine Bernasconi (chair of the board, 29/09/2025), Vincent Sainte-Catherine (ceo, 29/09/2025) and Vincent Sainte-Catherine (board member, 29/09/2025) (+2).
- Stepped down: Johan Ernst Wedell-Wedellsborg (board member, 29/09/2025), Michael Joseph Rossi (ceo, 29/09/2025) and Michael Joseph Rossi (board member, 29/09/2025) (+2).
Registrations, last 24 months
- 29/01/2026: Moved to Agern Alle 13, 2970 Hørsholm
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | 82,434 | 67,550 | 82,332 | 70,656 | 74,263 | 29,300 | −60.5% |
| Operating profit (EBIT) | 5,023 | −40,215 | −76,830 | −20,888 | −1,388 | −48,119 | −3,367.7% |
| Profit before tax | −1,202 | −42,088 | −85,686 | −27,749 | −12,500 | −58,946 | −371.6% |
| Net profit | −1,202 | −42,088 | −85,686 | −27,749 | −12,500 | −38,462 | −207.7% |
| Total assets | 52,038 | 61,472 | 22,906 | 56,658 | 26,470 | 15,043 | −43.2% |
| Equity | 2,833 | −39,255 | −84,941 | −112,690 | −125,190 | −163,652 | −30.7% |
| Liabilities | 49,205 | 100,727 | 107,847 | 169,348 | 151,661 | 178,695 | +17.8% |
| Cash and cash equivalents | 9,478 | 8,340 | 2,179 | 946 | 5,334 | 4,205 | −21.2% |
| Average number of employees | – | – | – | 59 | 56 | 53 | −5.4% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 163.7m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 6 years in a row
Net result has been negative in 2020–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 25/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 08/07/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 29/06/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 10/07/2023 | The company | PDFXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 30/06/2022 | The company | PDFXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 04/06/2021 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 913of 69,742 Better than 99% | No. 69,944of 69,964 Better than 0% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 6of 323 Better than 98% | No. 328of 329 Better than 0% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 1,314of 33,588 Better than 96% | No. 33,662of 33,687 Better than 0% |
| All companies of type A/S18,025 companies in the comparison | No. 4,471of 17,786 Better than 75% | No. 18,004of 18,024 Better than 0% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Y-mAbs Therapeutics A/SDKK 29.3m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Y-mAbs Therapeutics A/S−DKK 38.5m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Y-mAbs Therapeutics A/S−DKK 163.7m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Y-mAbs Therapeutics A/S13
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Y-mAbs Therapeutics, Inc.100%
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Vincent Sainte-Catherine | CEO | 29/09/2025 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Antoine Bernasconi | Chair of the board | 29/09/2025 |
| Vincent Sainte-Catherine | Board member | 29/09/2025 |
| Julien Forest | Board member | 29/09/2025 |
- Founders
- Y-mabs Therapeutics, Inc.
Former management (21)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Claus Juan Møller-San Pedro | Director | 27/08/2015 | 12/05/2022 |
| Claus Juan Møller-San Pedro | Board member | 27/08/2015 | 12/05/2022 |
| Thomas Gad | Chair of the board | 27/08/2015 | 11/05/2022 |
| Bo Kruse | Board member | 27/08/2015 | 20/12/2019 |
| Johan Ernst Wedell-Wedellsborg | Board member | 20/01/2016 | 28/10/2021 |
| Gregory Stephen Raskin | Board member | 20/01/2016 | 11/06/2020 |
| Ashutosh Tyagi | Board member | 18/01/2018 | 28/10/2021 |
| David Neil Gill | Board member | 18/01/2018 | 28/10/2021 |
| Michael Joachim Buschle | Board member | 18/01/2018 | 18/12/2018 |
| Jim Irvin Healy | Board member | 18/01/2018 | 28/10/2021 |
| Gérard Ber | Board member | 18/12/2018 | 28/10/2021 |
| Laura J. Hamill | Board member | 11/06/2020 | 28/10/2021 |
| Bo Kruse | Board member | 28/10/2021 | 11/05/2022 |
| Johan Ernst Wedell-Wedellsborg | Board member | 12/05/2022 | 29/09/2025 |
| Thomas Gad | CEO | 12/05/2022 | 28/11/2023 |
| Thomas Gad | Board member | 12/05/2022 | 30/07/2024 |
| Bo Kruse | Chair of the board | 12/05/2022 | 31/07/2024 |
| Michael Joseph Rossi | CEO | 28/11/2023 | 29/09/2025 |
| Michael Joseph Rossi | Board member | 29/11/2023 | 29/09/2025 |
| Thomas Gad | Chair of the board | 31/07/2024 | 29/09/2025 |
| Peter Paul Pfreundschuh | Board member | 28/05/2025 | 29/09/2025 |
Signing rule: Selskabet tegnes af den administrerende direktør, af to medlemmer af bestyrelsen i forening, af et medlem af bestyrelsen i forening med en direktør eller af den samlede bestyrelse.
Address and production units
1 active production unitsAgern Alle 13
2970 Hørsholm
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Y-mAbs Therapeutics A/S | Agern Alle 13, 2970 Hørsholm | 12 | 1020692894 |
Purpose
Virksomhedens formål er at udvikle lægemidler samen anden hermed forbunden virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
62 registered events20262 changesaccounts 1 · address 1
- AccountsAnnual report for 2025 published
- AddressMoved to Agern Alle 13, 2970 Hørsholm
202512 changesmanagement 10 · accounts 1 · industry 1
- ManagementJulien Forest appointed board member
- ManagementVincent Sainte-Catherine appointed board member
- ManagementVincent Sainte-Catherine appointed ceo
- ManagementAntoine Bernasconi appointed chair of the board
- ManagementPeter Paul Pfreundschuh stepped down as board member
- ManagementThomas Gad stepped down as chair of the board
- ManagementMichael Joseph Rossi stepped down as board member
- ManagementMichael Joseph Rossi stepped down as ceo
- ManagementJohan Ernst Wedell-Wedellsborg stepped down as board member
- AccountsAnnual report for 2024 published
- ManagementPeter Paul Pfreundschuh appointed board member
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20244 changesmanagement 3 · accounts 1
- ManagementThomas Gad appointed chair of the board
- ManagementBo Kruse stepped down as chair of the board
- ManagementThomas Gad stepped down as board member
- AccountsAnnual report for 2023 published
20234 changesmanagement 3 · accounts 1
- ManagementMichael Joseph Rossi appointed board member
- ManagementMichael Joseph Rossi appointed ceo
- ManagementThomas Gad stepped down as ceo
- AccountsAnnual report for 2022 published
202210 changesaccounts 1 · capital 1 · management 8
- AccountsAnnual report for 2021 published
- CapitalShare capital changed from 3,166,666 DKK to 9,833,332 DKK
- ManagementThomas Gad appointed ceo
- ManagementBo Kruse appointed chair of the board
- ManagementThomas Gad appointed board member
- ManagementJohan Ernst Wedell-Wedellsborg appointed board member
- ManagementClaus Juan Møller-San Pedro stepped down as board member
- ManagementClaus Juan Møller-San Pedro stepped down as director
- ManagementBo Kruse stepped down as board member
- ManagementThomas Gad stepped down as chair of the board
20218 changesmanagement 7 · accounts 1
- ManagementBo Kruse appointed board member
- ManagementLaura J. Hamill stepped down as board member
- ManagementGérard Ber stepped down as board member
- ManagementAshutosh Tyagi stepped down as board member
- ManagementJim Irvin Healy stepped down as board member
- ManagementDavid Neil Gill stepped down as board member
- ManagementJohan Ernst Wedell-Wedellsborg stepped down as board member
- AccountsAnnual report for 2020 published
20202 changesmanagement 2
- ManagementLaura J. Hamill appointed board member
- ManagementGregory Stephen Raskin stepped down as board member
20192 changescapital 1 · management 1
- CapitalShare capital changed from 2,333,333 DKK to 3,166,666 DKK
- ManagementBo Kruse stepped down as board member
20188 changesmanagement 6 · capital 1 · address 1
- ManagementGérard Ber appointed board member
- ManagementMichael Joachim Buschle stepped down as board member
- CapitalShare capital changed from 1,500,000 DKK to 2,333,333 DKK
- AddressMoved to Agern Alle 11, 2970 Hørsholm
- ManagementAshutosh Tyagi appointed board member
- ManagementJim Irvin Healy appointed board member
- ManagementMichael Joachim Buschle appointed board member
- ManagementDavid Neil Gill appointed board member
20172 changescapital 1 · address 1
- CapitalShare capital changed from 1,000,000 DKK to 1,500,000 DKK
- AddressMoved to Rungsted Strandvej 113, 2960 Rungsted Kyst
20162 changesmanagement 2
- ManagementGregory Stephen Raskin appointed board member
- ManagementJohan Ernst Wedell-Wedellsborg appointed board member
20156 changesfounded 1 · management 4 · ownership 1
- FoundedRegistered as Y-mAbs Therapeutics A/S
- ManagementClaus Juan Møller-San Pedro appointed board member
- ManagementBo Kruse appointed board member
- ManagementThomas Gad appointed chair of the board
- ManagementClaus Juan Møller-San Pedro appointed director
- OwnershipY-mAbs Therapeutics, Inc. registered as owner (100%)
Related companies
Same industry in Rudersdal
- Dhi A/S345 employees
- Bioneer A/S82 employees
- Dansk Fundamental Metrologi A/S55 employees
- Glycom A/S51 employees
- Evaxion A/S46 employees
- Presto Engineering Denmark ApS39 employees
Same people in management
- Joe & The Juice A/Svia Johan Ernst Wedell-Wedellsborg
- Genmab A/Svia Bo Kruse
- Emmerys ApSvia Johan Ernst Wedell-Wedellsborg
- Capio A/Svia Claus Juan Møller-San Pedro
- Stena Bulk A/Svia Johan Ernst Wedell-Wedellsborg
- Zuuvi ApSvia Johan Ernst Wedell-Wedellsborg
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.